Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Yelena Y. Janjigian, MD, discusses results from the phase III JAVELIN Gastric 100 study evaluating avelumab in gastric or gastroesophageal cancer.

Eileen O'Reilly, MD, discusses the potential role of veliparib in pancreatic cancer.

David H. Ilson, MD, PhD, discusses the utility of zolbetuximab in claudin-positive gastric cancers.

Ghassan K. Abou-Alfa, MD, discusses sequencing challenges in metastatic hepatocellular carcinoma.

Chau T. Dang, MD, discusses recent treatment breakthroughs and emerging agents in HER2-positive breast cancer.

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial, which evaluated the efficacy of fixed-duration treatment with venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia.

Eileen O'Reilly, MD, discusses germline testing in pancreatic cancer.

Ghassan K. Abou-Alfa, MD, discusses the most intriguing updates in hepatocellular carcinoma, anticipated sequencing challenges, and novel modalities on the horizon.

Gopa Iyer, MD, discusses the challenges faced with identifying an optimal screening methodology to select patients with bladder cancer for FGFR inhibitor therapy.

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the updated results of the phase Ib/II EV-103 trial (NCT03288545) with enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) in patients with locally advanced or metastatic urothelial carcinoma.

Maxine S. Jochelson, MD, discusses the limitations of mammography and ultrasound in screening patients for breast cancer.

Fam-trastuzumab deruxtecan-nxki, a HER2-directed antibody­–drug conjugate, demonstrated significant clinical activity in multiple non-breast, non-gastric cancer solid tumor types.

Craig Sauter, MD, discusses results of a retrospective, real-world review of patients with hematologic malignancies who developed cytopenia post-CAR T-cell therapy.

Gopa Iyer, MD, discusses investigational FGFR inhibitors in metastatic urothelial carcinoma.

We recently traveled to Summit, New Jersey for a State of the Science Summit on Lung Cancer, which featured insights from Memorial Sloan Kettering Cancer Center faculty.

Ghassan K. Abou-Alfa, MD, provides perspective on the accelerated approval of nivolumab and ipilimumab in advanced hepatocellular carcinoma.

Gopa Iyer, MD, discusses treatment-emergent hyperphosphatemia with erdafitinib in patients with metastatic urothelial cancer.

Chung-Han (Joe) Lee, MD, PhD, discussed advancements in metastatic renal cell carcinoma regarding combination regimens and ongoing questions of how to treat patients upon disease progression.

Chung-Han Lee, MD, PhD, discusses treatment options for patients with metastatic renal cell carcinoma.

Eileen O'Reilly, MD, Winthrop Rockefeller Endowed Chair in Medical Oncology, co-director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research, section head, Hepatopancreaticobilary and Neuroendocrine Cancers, and medical oncologist, Memorial Sloan Kettering Cancer Center, discusses

Raajit K. Rampal, MD, PhD, discusses investigational agents in myeloproliferative neoplasms.

Martin H. Voss, MD, discusses the phase I/II trial evaluating MEDI0680 plus durvalumab in metastatic renal cell carcinoma and what similar research efforts lie ahead.

Andrea Cercek, MD, discusses targeted strategies in BRAF-mutant metastatic colorectal cancer.

Neil H. Segal, MD, PhD, discusses the current role of immunotherapy in colorectal cancer and the work being done to define its role in earlier-line settings and among patients with microsatellite stable disease.

James J. Harding, MD, discusses the evolving treatment landscape in frontline hepatocellular carcinoma and ongoing trials that may revolutionize the space.

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the impact of tumor sidedness on frontline treatment decisions in metastatic colorectal cancer (mCRC).

Ghassan K. Abou-Alfa, MD, discusses the treatment options that have emerged in advanced hepatocellular carcinoma and the work being done to determine optimal sequencing strategies.

David H. Ilson, MD, PhD, discusses TKI combinations under investigation in gastric cancer.

David H. Ilson, MD, PhD, discusses the treatment landscape of advanced gastric cancer and the research being done to define a role for novel agents in this space.